The impact of caffeine on vasodilator stress perfusion studies

Journal of Nuclear Cardiology

Volumn 11, Issue 4, 2004, Pages 506-511

  Lapeyre III, Andre C ^a   Goraya, Tauqir Y ^a   Johnston, Donald L ^a   Gibbons, Raymond J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; AMMONIA; CAFFEINE; CIMETIDINE; DIPYRIDAMOLE; NITROGEN 13; ORAL CONTRACEPTIVE AGENT; PHOSPHODIESTERASE; PLACEBO; RIFAMPICIN; THALLIUM 201; THEOPHYLLINE; XANTHINE DERIVATIVE;

ASTHMA; BINDING AFFINITY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; EXERCISE TEST; FOOD COMPOSITION; FOOD INTAKE; HEART ARRHYTHMIA; HEART MUSCLE PERFUSION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NON INVASIVE MEASUREMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SUPRAVENTRICULAR PREMATURE BEAT; VASODILATATION;

EID: 4243134949     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2004.04.003     Document Type: Article

References (42)

1. Albro P.C. Gould K.L. Westcott R.J. et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilatation. III. Clinical trial Am J Cardiol 42 1978 751-760
2. Eagle K.A. Coley C.M. Newell J.B. et al. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery Ann Intern Med 110 1989 859-866
3. Leppo J.A. O'Brien J. Rothendler J.A. Getchell J.D. Lee V.W. Dipyridamole-thallium-201 scintigraphy in the prediction of future cardiac events after acute myocardial infarction N Engl J Med 310 1984 1014-1018
4. Verani M.S. Pharmacologic stress testing and other alternative techniques in the diagnosis of coronary artery disease In: Iskandrian A.S. Verani M.S. (Eds.) Nuclear cardiac imaging: principles and applications 2003 164-189 OxfordNew York
5. Cerqueira M.D. Verani M.S. Schwaiger M. Heo J. Iskandrian A.S. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry [comment] J Am Coll Cardiol 23 1994 384-389
6. Johnston D.L. Daley J.R. Hodge D.O. Hopfenspirger M.R. Gibbons R.J. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2,000 patients Mayo Clin Proc 70 1995 331-336
7. American Society of Nuclear Cardiology Updated imaging guidelines for nuclear cardiology procedures, part 1 [comment] J Nucl Cardiol 8 2001 G5-58
8. Klocke F.J. Baird M.G. Lorell B.H. et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging) J Am Coll Cardiol 42 2003 1318-1333
9. Smits P. Corstens F.H. Aengevaeren W.R. Wackers F.J. Thien T. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion J Nucl Med 32 1991 1538-1541
10. Frishman W.H. Sonnenblick E.H. Cardiovascular pharmacotherapeutics 1997 McGraw-Hill Health Professions DivisionNew York
11. Barone J.J. Roberts H.R. Caffeine consumption Food Chem Toxicol 34 1996 119-129
12. Blanchard J. Sawers S.J. The absolute bioavailability of caffeine in man Eur J Clin Pharmacol 24 1983 93-98
13. Balogh A. Harder S. Vollandt R. Staib A.H. Intra-individual variability of caffeine elimination in healthy subjects [published erratum appears in Int J Clin Pharmacol Ther Toxicol 1993;31:208] Int J Clin Pharmacol Ther Toxicol 30 1992 383-387
14. Butler M.A. Lang N.P. Young J.F. et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites Pharmacogenetics 2 1992 116-127
15. Grant D.M. Tang B.K. Kalow W. Variability in caffeine metabolism Clin Pharmacol Ther 33 1983 591-602
16. Patwardhan R.V. Desmond P.V. Johnson R.F. Schenker S. Impaired elimination of caffeine by oral contraceptive steroids J Lab Clin Med 95 1980 603-608
17. Parsons W.D. Neims A.H. Effect of smoking on caffeine clearance Clin Pharmacol Ther 24 1978 40-45
18. Wietholtz H. Zysset T. Marschall H.U. Generet K. Matern S. The influence of rifampin treatment on caffeine clearance in healthy man J Hepatol 22 1995 78-81
19. May D.C. Jarboe C.H. VanBakel A.B. Williams W.M. Effects of cimetidine on caffeine disposition in smokers and nonsmokers Clin Pharmacol Ther 31 1982 656-661
20. Statland B.E. Demas T.J. Serum caffeine half-lives. Healthy subjects vs. patients having alcoholic hepatic disease Am J Clin Pathol 73 1980 390-393
21. Hirvonen J. Jaaskelainen I.P. Naatanen R. Sillanaukee P. Adenosine A1/A2a receptors mediate suppression of mismatch negativity by ethanol in humans Neurosci Lett 278 2000 57-60
22. El Yacoubi M. Ledent C. Parmentier M. Costentin J. Vaugeois J.M. Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade Neuropharmacology 45 2003 977-985
23. Smits P. Lenders J.W. Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans Clin Pharmacol Ther 48 1990 410-418
24. Smith J.M. Pearson S. Marks V. Plasma caffeine concentration in outpatients Lancet 2 1982 985-986
25. Majd-Ardekani J. Clowes P. Menash-Bonsu V. Nunan T.O. Time for abstention from caffeine before an adenosine myocardial perfusion scan Nucl Med Commun 21 2000 361-364
26. Jacobson A.F. Cerqueira M.D. Raisys V. Shattuc S. Serum caffeine levels after 24 hours of caffeine abstention: observations on clinical patients undergoing myocardial perfusion imaging with dipyridamole or adenosine Eur J Nucl Med 21 1994 23-26
27. Moser G.H. Schrader J. Deussen A. Turnover of adenosine in plasma of human and dog blood Am J Physiol 256 1989 C799-806
28. Ammon H.P. Biochemical mechanism of caffeine tolerance Arch Pharm 324 1991 261-267
29. Smits P. Straatman C. Pijpers E. Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine Clin Pharmacol Ther 50 1991 529-537
30. Zheng X.M. Williams R.C. Serum caffeine levels after 24-hour abstention: clinical implications on dipyridamole (201)Tl myocardial perfusion imaging J Nucl Med Technol 30 2002 123-127
31. Bottcher M. Czernin J. Sun K.T. Phelps M.E. Schelbert H.R. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation J Nucl Med 36 1995 2016-2021
32. Aqel R.A. Zoghbi G.J. Trimm J.R. Baldwin S.A. Iskandrian A.E. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease Am J Cardiol 93 2004 343-346
33. Daley P.J. Mahn T.H. Zielonka J.S. et al. Effect of maintenance oral theophylline on dipyridamole-thallium-201 myocardial imaging using SPECT and dipyridamole-induced hemodynamic changes Am Heart J 115 1988 1185-1192
34. Smits P. Aengevaeren W.R. Corstens F.H. Thien T. Caffeine reduces dipyridamole-induced myocardial ischemia J Nucl Med 30 1989 1723-1726
35. Smits P. Thien T. van't Laar A. Circulatory effects of coffee in relation to the pharmacokinetics of caffeine Am J Cardiol 56 1985 958-963
36. Tiffin P. Ashton H. Marsh R. Kamali F. Pharmacokinetic and pharmacodynamic responses to caffeine in poor and normal sleepers Psychopharmacology 121 1995 494-502
37. Laffey J.G. Carroll M. Donnelly N. Boylan J.F. Instructions for ambulatory surgery-patient comprehension and compliance Ir J Med Sci 167 1998 160-163
38. Malins A.F. Do they do as they are instructed? A review of out-patient anaesthesia Anaesthesia 33 1978 832-835
39. Hurwitz R. Lyons K. Taketa R. Adenosine challenge and boost protocols: new tools for myocardial perfusion imaging Clin Nucl Med 24 1999 92-93
40. Coca-Cola Web site. Available from: URL: http://www2.coca-cola.con/ourcompany/columns_caffeine.html. Accessed Jan 20, 2004
41. Pepsi Web site. Available from: URL: http://www.pepsi.com/help/faqs/ faq.php?viewall=yes-category=pepsi_brands#top. Accessed Jan 20, 2004
42. National Soft Drink Association Web site. Available from: URL: http://www.nsda.org/WhatsIn/caffeinecontent.html. Accessed Jan 20, 2004